Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.30 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.30 |
| ▸ | WDR77 | Q9BQA1 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3584726 | 0.95 | ALDH1A1 (0.35) | POLBKCNH2ALDH1A1PRMT5WDR77 | |
| SCHEMBL3577215 | 0.90 | PRMT5 (0.33) | POLBHPGDKCNH2ALDH1A1PRMT5 | |
| SCHEMBL3575364 | 0.88 | PRMT5 (0.36) | POLBHPGDKCNH2ALDH1A1PRMT5 | |
| SCHEMBL3580931 | 0.87 | PRMT5 (0.35) | POLBHPGDKCNH2ALDH1A1PRMT5 | |
| SCHEMBL3586101 | 0.87 | ALDH1A1 (0.35) | POLBKCNH2ALDH1A1PRMT5WDR77 | |
| SCHEMBL3585555 | 0.87 | ALDH1A1 (0.36) | POLBHPGDKCNH2ALDH1A1PRMT5 | |
| SCHEMBL5672044 | 0.86 | ALDH1A1 (0.30) | ALDH1A1PRMT5WDR77 | |
| SCHEMBL3582399 | 0.86 | ALDH1A1 (0.38) | POLBHPGDALDH1A1PRMT5WDR77 | |
| SCHEMBL5071426 | 0.85 | ALDH1A1 (0.35) | POLBKCNH2ALDH1A1PRMT5WDR77 | |
| SCHEMBL3424830 | 0.85 | POLB (0.35) | POLBHPGDALDH1A1PRMT5WDR77 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | claimed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | claimed |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2010-01-14 | — | — | US | disclosed |
| US-7629332-B2 | Nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNISERVICES LIMITED (NZ) | 2009-12-08 | — | — | US | disclosed |
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | AUCKLAND UNIVERVICES LIMITED (NZ) | 2007-02-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070032455-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, PNP | POLB 3572/4885HPGD 109/4885KCNH2 4366/4885 |
| US-20100010094-A1 | Novel nitrophenyl mustard and nitrophenylaziridine alcohols and their corresponding phosphates and their use as targeted cytotoxic agents | NAPRT, NTPCR, QDPR | POLB 3718/4885HPGD 111/4885KCNH2 4161/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.